Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
- PMID: 25579058
- DOI: 10.1016/j.addr.2015.01.002
Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
Abstract
The enhanced permeability and retention (EPR) effect of solid tumors as seen with nanomedicines and macromolecular drugs is well known. However, many researchers appear to lack a full understanding of this effect. The effect varies depending on a patient's pathological and physiological characteristics and clinical condition. When a patient's systolic blood pressure is low side of about 90mmHg instead of 120-130mmHg, the hydrodynamic force pushing blood from the luminal side of a vessel into tumor tissue becomes significantly low, which results in a low EPR. Also, a vascular embolism in a tumor may impede blood flow and the EPR. Here, I describe the background of the EPR effect, heterogeneity of this effect, physiological and pathological factors affecting the effect, the EPR effect in metastatic tumors, artifacts of the EPR effect with micellar and liposomal drugs, problems of macromolecular drug stability and drug release, and access to target sites.
Keywords: Anticancer drugs; EPR effect artifacts; EPR effect dependence on time and molecular size; EPR effect dynamics; Macromolecular drugs; Nanomedicines.
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
-
Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.Bioconjug Chem. 2010 May 19;21(5):797-802. doi: 10.1021/bc100070g. Bioconjug Chem. 2010. PMID: 20397686 Review.
-
Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.J Drug Target. 2007 Aug-Sep;15(7-8):457-64. doi: 10.1080/10611860701539584. J Drug Target. 2007. PMID: 17671892 Review.
-
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.Eur J Pharm Biopharm. 2009 Mar;71(3):409-19. doi: 10.1016/j.ejpb.2008.11.010. Epub 2008 Dec 3. Eur J Pharm Biopharm. 2009. PMID: 19070661 Review.
-
Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.Expert Opin Drug Deliv. 2015 Jan;12(1):53-64. doi: 10.1517/17425247.2014.955011. Epub 2014 Nov 26. Expert Opin Drug Deliv. 2015. PMID: 25425260 Review.
-
S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes.J Control Release. 2015 Nov 10;217:1-9. doi: 10.1016/j.jconrel.2015.08.036. Epub 2015 Aug 22. J Control Release. 2015. PMID: 26302904
Cited by
-
KHSRP knockdown inhibits papillary renal cell carcinoma progression and sensitizes to gemcitabine.Front Pharmacol. 2024 Oct 8;15:1446920. doi: 10.3389/fphar.2024.1446920. eCollection 2024. Front Pharmacol. 2024. PMID: 39439895 Free PMC article.
-
Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects.Int J Nanomedicine. 2024 Oct 2;19:9459-9486. doi: 10.2147/IJN.S466396. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39371481 Free PMC article. Review.
-
Transvascular transport of nanocarriers for tumor delivery.Nat Commun. 2024 Sep 17;15(1):8172. doi: 10.1038/s41467-024-52416-0. Nat Commun. 2024. PMID: 39289401 Free PMC article. Review.
-
Inulin Amphiphilic Copolymer-Based Drug Delivery: Unraveling the Structural Features of Graft Constructs.Pharmaceutics. 2024 Jul 23;16(8):971. doi: 10.3390/pharmaceutics16080971. Pharmaceutics. 2024. PMID: 39204316 Free PMC article.
-
Delivery of miRNAs Using Nanoparticles for the Treatment of Osteosarcoma.Int J Nanomedicine. 2024 Aug 22;19:8641-8660. doi: 10.2147/IJN.S471900. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39188861 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
